RUCDR Infinite Biologics Selects NuGEN as Corporate Sponsor and Genomic Sample Processing Partner
Piscataway, N.J. (PRWEB) August 27, 2013 -- RUCDR Infinite Biologics, the world’s largest university-based biorepository, has added NuGEN Technologies to its group of technology sponsors. A unit of Rutgers, The State University of New Jersey, RUCDR Infinite Biologics currently stores more than 12 million biosamples.
Dr. Andy Brooks, chief operating officer of RUCDR Infinite Biologics, said: “The RUCDR corporate sponsorship program is the cornerstone of the relationship with our most valued technology suppliers. It enables us to align the activities of our partners with the strategic goals of RUCDR and to offer the most competitive and cutting-edge services to our pharmaceutical, diagnostic, and clinical research customers worldwide. NuGEN has been a valued partner from the inception of RUCDR, providing genomic sample preparation solutions that have become an integral part of our sample archiving and analysis services.”
RUCDR assists researchers worldwide through provision of the highest quality biomaterials, technical consultation, and logistic support and plays a key role in research into the genetic causes of common diseases. In the course of a long-standing and collaborative partnership, many of the technology innovations developed at NuGEN have first been tested and implemented as part of the standard operating procedures at RUCDR.
Ms. Elizabeth Hutt, chief executive officer of NuGEN, said: “NuGEN has enjoyed a long and productive partnership with RUDCR and we are honored to join its select group of technology sponsors. It is incredibly important for us to work closely with our customers, particularly organizations like RUCDR, who are leaders in their field and demand the highest levels of performance and service from their suppliers. The partnership has given us a unique insight into the needs of scientists working in clinical research and routine clinical testing.”
Currently, NuGEN and RUCDR have several collaborative projects underway including sample preparation methods for RNA-seq analysis of single cells and rapid and convenient target enrichment technology for NGS analysis. In addition, RUCDR was the first biorespository to implement NuGEN’s RNA sample archiving technology to generate a more stable and renewable cDNA resource from limited quantities of RNA and reduce variability in downstream analysis between different labs and users. This has had a tremendous impact across many government, foundation, and industrial collections by creating renewable resources for now and in the future. Details of these and other sample preparation technologies will be presented by NuGEN at the RUCDR Translational Research Forum, “Innovative Bioprocessing and Comprehensive Sample Management,” to be held at Rutgers Oct. 3, 2013 (register to attend at http://translationalresearchforum.eventbrite.com).
RUCDR Infinite Biologics offers a complete and integrated selection of biological sample processing, analysis, and biorepository services to government agencies, academic institutions, foundations, and biotechnology and pharmaceutical companies within the global scientific community. RUCDR Infinite Biologics provides DNA, RNA, and cell lines with clinical data to hundreds of research laboratories for studies on mental health and developmental disorders, drug and alcohol abuse, diabetes, and digestive, liver, and kidney diseases. RUCDR recently received a $44.5 million Cooperative Agreement award from the National Institute of Mental Health to support its NIMH Center for Collaborative Genomics Research on Mental Disorders, which provides services to NIMH-funded scientists engaged in genomic research on mental disorders. The new grant will enable RUCDR Infinite Biologics to collect, process, and analyze blood and tissue samples from NIMH-funded scientists nationwide and provide advanced statistical and analytic consultation. RUCDR Infinite Biologics recently completed an $11.4 million expansion and renovation. Learn more at http://www.rucdr.org.
NuGEN Technologies is a San Carlos, Calif., company focused on innovative sample preparation solutions for RNA and DNA that enable life scientists to do more with less. With reagent solutions that are quick, easy to use, and amenable to automation, NuGEN empowers researchers to prepare genomic samples of any size, from almost any source, regardless of the intended application or technology platform. Learn more at http://www.nugeninc.com.
[NuGEN is a registered trademark of NuGEN Technologies, Inc.]
Edward Tate, Rutgers University, http://vpr.rutgers.edu, 848-445-3153, [email protected]
Share this article